Skin Cancer of the Head and Neck
Cutaneous squamous cell carcinoma (cSCC) · Basal cell carcinoma (BCC) · Head and neck melanoma · Merkel cell carcinoma | ICD-10 C43–C44 (head and neck skin sites)
Skin cancers of the head and neck are tumours arising on chronically sun-exposed skin — basal cell carcinoma, cutaneous squamous cell carcinoma and melanoma being the most common. They are especially frequent in fair-skinned populations in Australia, New Zealand and North America, and the head and neck is the most common site because it receives the highest lifetime UV dose.
The head, face, ears, scalp and neck account for a disproportionate share of skin cancers even though they are a small fraction of body surface area. Basal cell carcinoma is the commonest and rarely metastasises but can be locally destructive around the eyes, nose and ear. Cutaneous squamous cell carcinoma of the head and neck has a higher risk of perineural spread and nodal metastasis than cSCC elsewhere on the body; melanoma is less common but causes most skin cancer deaths.
Lesions on the ear, scalp, temple and lip deserve particular respect: these sites have thin tissue, rich lymphatic drainage and proximity to cranial nerves. A non-healing sore, a changing mole or a persistent scaly patch on the head or neck should be examined with dermoscopy and biopsied rather than treated as eczema or an infection.
Where in the world is skin cancer of the head and neck common?
millions of skin cancers each year worldwide; GLOBOCAN 2022 estimated ASR 3.2 for melanoma of skin and 10.4 for non-melanoma skin cancer per 100,000 were estimated worldwide in 2022 (ASR 3.2 (melanoma) and 10.4 (non-melanoma skin cancer) per 100,000; mortality ASR 0.5 and 0.6 respectively).
Non-melanoma incidence figures exclude basal cell carcinoma in GLOBOCAN tables, so they substantially undercount the true number of skin cancers treated.
| Region / country | What the data show |
|---|---|
| Australia & New Zealand | The highest population skin cancer burden in the world, driven by high ambient UV and a predominantly fair-skinned population; head and neck sites are the most commonly treated locations. |
| North America | High melanoma and keratinocyte cancer incidence, particularly in older fair-skinned adults and in states with high UV exposure. |
| Northern & Western Europe | Rising melanoma incidence in fair-skinned populations; intermittent intense sun exposure and tanning-bed use are important drivers. |
| Southern Europe & the Mediterranean | High cumulative sun exposure among outdoor workers, with substantial cSCC and lip cancer burdens. |
| Organ-transplant recipients worldwide | Chronic immunosuppression markedly increases cSCC risk independent of geography, often with multiple and more aggressive head and neck lesions. |
What are the risk factors?
- Cumulative ultraviolet radiation and a history of blistering sunburn, especially in childhood
- Fair skin, light hair/eye colour, freckling and inability to tan
- Tanning-bed use and intermittent intense recreational sun exposure
- Chronic immunosuppression (organ transplantation, HIV, some haematological diseases)
- Previous skin cancer, actinic keratoses, arsenic or ionising radiation exposure
- Increasing age, male sex and outdoor occupation
What are the signs and symptoms?
- A sore or crusted spot on the face, ear, scalp or neck that does not heal within a few weeks
- A pearly or translucent bump with visible vessels (typical of basal cell carcinoma)
- A scaly, tender or rapidly growing keratotic nodule (typical of cutaneous SCC)
- A changing mole — asymmetry, irregular border, varied colour, increasing diameter, evolution (ABCDE)
- New numbness, tingling, facial weakness or pain near a lesion (possible perineural invasion)
- Lumps in front of the ear, in the parotid region or in the neck (nodal metastasis)
Two-to-three-week rule: any head or neck symptom that persists beyond two to three weeks should be examined by an ENT specialist with an endoscope — pain is usually a late feature, not an early one.
How is it diagnosed and staged?
- Full skin and head/neck examination with dermoscopy by an experienced clinician
- Excisional biopsy for suspected melanoma with Breslow depth reported; incisional or punch biopsy for large facial lesions
- Pathology assessment of histological subtype, Breslow thickness, ulceration, margins and perineural invasion
- Ultrasound ± FNA of regional nodes (including parotid nodes) for high-risk cSCC, melanoma or Merkel cell carcinoma
- MRI with contrast when perineural invasion or deep extension is suspected; CT/PET-CT for advanced disease
- Sentinel lymph node biopsy for melanoma of appropriate thickness and selected high-risk tumours
Melanoma uses AJCC staging based primarily on Breslow thickness, ulceration, nodal involvement and distant metastasis. Cutaneous SCC of the head and neck uses a separate high-risk framework that considers size, depth, perineural invasion, ear/lip location, immunosuppression and nodal disease; a "small" ear lesion can therefore be high stage.
What are the treatment options?
- Wide local excision with confirmed margins; Mohs micrographic surgery for facial lesions where tissue preservation matters
- Reconstruction with local flaps or skin grafts, often in partnership with plastic/oculoplastic surgery for eyelid, nose and ear defects
- Sentinel lymph node biopsy for eligible melanomas; therapeutic neck/parotid dissection and adjuvant radiotherapy for nodal disease
- Radiotherapy for inoperable lesions, perineural invasion, positive margins or patients unfit for surgery
- Immunotherapy (PD-1 ± CTLA-4 inhibitors) and BRAF/MEK targeted therapy for advanced melanoma; PD-1 inhibitors for advanced cSCC and Merkel cell carcinoma
- Field treatment of actinic keratoses and structured lifelong skin surveillance
Decisions should be made by a multidisciplinary tumour board, with speech, swallowing and appearance considered alongside cancer control. See how treatment changes with stage →
What is the prognosis?
Localised basal cell carcinoma is almost always curable, and thin localised melanoma has five-year survival commonly above 90%. Prognosis worsens with thick or ulcerated melanoma, nodal metastasis, head and neck cSCC with perineural invasion, and immunosuppression. Because UV damage is field-wide, new primary skin cancers are common and long-term surveillance is essential.
Survival figures are population averages from registry data, not predictions for an individual. See the follow-up schedule →
Can it be prevented?
- Daily broad-spectrum sunscreen, protective clothing and wide-brimmed hats, and shade at peak UV hours
- Avoid tanning beds entirely
- Regular self-examination of the face, ears, scalp and neck; periodic clinician skin checks for high-risk patients
- Prompt biopsy of any non-healing or changing lesion, especially on the ear, scalp or lip
- Enhanced dermatology surveillance and sun protection for organ-transplant recipients
Prevention by region: HPV vaccine, areca nut, tobacco and UV →
Treatment in China for international patients
Head and neck skin cancer is less common in China than in Australia, New Zealand or North America, so international patients should confirm that the treating unit has experience with Mohs surgery, parotid/neck nodal management, perineural imaging and facial reconstruction, and can provide the immunotherapy agents used at home.
- Bring the original pathology slides, Breslow depth or high-risk features, dermoscopic photographs and any sentinel node results.
- Ask whether the planned wide local excision margin and reconstruction match the standards in your home country, and whether Mohs surgery is available.
- If immunotherapy or targeted therapy is part of your plan, confirm the exact drug, dose, cycle schedule, stock availability and price in writing before travel.
- Request the full pathology and operative report in English so your dermatologist or oncologist can continue surveillance.
Cost guidance: As an illustrative planning range, wide local excision with local flap reconstruction is commonly budgeted at ¥20,000–¥80,000 (about US$2,800–11,000); neck/parotid dissection with adjuvant radiotherapy ¥80,000–¥180,000. Modern immunotherapy is charged per cycle and can dominate the total. These figures are not a quotation.
Compare the pathway, records checklist and aftercare planning on the international patients page.
All 14 questions about skin cancer of the head and neck
Each question has its own page with a direct answer, practical detail and the sources behind it — the same structure used on Dr. Liu’s Chinese knowledge base.
Understanding the disease
4 questionsWhat the tumour is, where in the world it is common, who gets it and why.
Symptoms & diagnosis
3 questionsThe warning signs, the biopsy, the scans and what staging actually means.
Treatment
2 questionsSurgery, radiotherapy, chemotherapy, immunotherapy and organ-preserving options.
Prognosis & follow-up
1 questionSurvival figures in context, recurrence risk and the follow-up schedule.
Prevention & risk
2 questionsHPV vaccination, tobacco and areca nut, UV protection and occupational exposure.
Treatment in China
2 questionsWhat international patients should prepare, timelines, costs and aftercare.
Frequently asked questions
What is skin cancer of the head and neck?
Skin cancers of the head and neck are tumours arising on chronically sun-exposed skin — basal cell carcinoma, cutaneous squamous cell carcinoma and melanoma being the most common. They are especially frequent in fair-skinned populations in Australia, New Zealand and North America, and the head and neck is the most common site because it receives the highest lifetime UV dose.
Where in the world is skin cancer of the head and neck most common?
Skin Cancer of the Head and Neck is not evenly distributed: the highest-burden regions are Australia & New Zealand, North America and Northern & Western Europe. In 2022 there were millions of skin cancers each year worldwide; GLOBOCAN 2022 estimated ASR 3.2 for melanoma of skin and 10.4 for non-melanoma skin cancer per 100,000 worldwide (ASR 3.2 (melanoma) and 10.4 (non-melanoma skin cancer) per 100,000; mortality ASR 0.5 and 0.6 respectively), with marked country-to-country variation driven by local exposures such as tobacco, areca nut, oncogenic viruses, ultraviolet radiation and occupational carcinogens.
What are the risk factors for skin cancer of the head and neck?
The main recognised risk factors for skin cancer of the head and neck are cumulative ultraviolet radiation and a history of blistering sunburn, especially in childhood, fair skin, light hair/eye colour, freckling and inability to tan and tanning-bed use and intermittent intense recreational sun exposure. Risks differ by region: Australia & New Zealand has a distinctive exposure pattern, so a patient's country of residence is part of the risk assessment. Having a risk factor does not mean a person will develop cancer.
What are the early signs of skin cancer of the head and neck?
The common early signs are a sore or crusted spot on the face, ear, scalp or neck that does not heal within a few weeks, a pearly or translucent bump with visible vessels (typical of basal cell carcinoma), a scaly, tender or rapidly growing keratotic nodule (typical of cutaneous SCC) and a changing mole — asymmetry, irregular border, varied colour, increasing diameter, evolution (ABCDE). Head and neck tumours often cause mild, one-sided symptoms that mimic a cold, a dental problem or a sore throat. Any symptom in the head or neck that persists for more than two to three weeks needs an ENT examination rather than repeated antibiotics.
How is skin cancer of the head and neck diagnosed and staged?
Diagnosis requires a tissue biopsy read by a head and neck pathologist, supported by endoscopic examination and contrast CT or MRI of the neck; PET-CT is added when nodal or distant spread is suspected. Staging uses the AJCC TNM system and guides whether surgery, radiotherapy, chemoradiotherapy or systemic therapy is the primary treatment.
What are the treatment options for skin cancer of the head and neck?
Treatment is stage- and site-specific, and usually combines wide local excision with confirmed margins; Mohs micrographic surgery for facial lesions where tissue preservation matters, reconstruction with local flaps or skin grafts, often in partnership with plastic/oculoplastic surgery for eyelid, nose and ear defects and sentinel lymph node biopsy for eligible melanomas; therapeutic neck/parotid dissection and adjuvant radiotherapy for nodal disease. Early-stage disease is generally treated with one modality (surgery or radiotherapy), while locally advanced disease needs combined modality treatment planned by a multidisciplinary team.
What is the prognosis for skin cancer of the head and neck?
Localised basal cell carcinoma is almost always curable, and thin localised melanoma has five-year survival commonly above 90%. Prognosis worsens with thick or ulcerated melanoma, nodal metastasis, head and neck cSCC with perineural invasion, and immunosuppression. Because UV damage is field-wide, new primary skin cancers are common and long-term surveillance is essential.
Can skin cancer of the head and neck be prevented?
Many cases are preventable. The most useful steps for skin cancer of the head and neck are daily broad-spectrum sunscreen, protective clothing and wide-brimmed hats, and shade at peak UV hours, avoid tanning beds entirely and regular self-examination of the face, ears, scalp and neck; periodic clinician skin checks for high-risk patients. Prevention works best before exposure begins, but stopping tobacco, areca nut and heavy alcohol use still lowers risk after many years of use.
Why are skin cancers so common on the head and neck?
The face, ears, scalp and neck receive the highest lifetime cumulative ultraviolet dose of any body area and are rarely covered by clothing. Combined with thin skin, plentiful lymphatics and proximity to cranial nerves, this makes the head and neck both the most frequent site of skin cancer and the site where relatively small tumours can behave aggressively.
What is the difference between basal cell carcinoma, squamous cell carcinoma and melanoma?
Basal cell carcinoma grows slowly and almost never spreads to nodes but can destroy local tissue, especially around the eye, nose and ear. Cutaneous squamous cell carcinoma grows faster and can spread to parotid or neck nodes, particularly on the head and neck. Melanoma is less common but has the greatest metastatic potential and causes most skin cancer deaths.
What does perineural invasion mean in a head and neck skin cancer?
Perineural invasion means tumour cells are tracking along a nerve sheath. On the head and neck it is clinically important because it can cause pain, numbness, tingling or facial weakness, allows spread well beyond the visible lesion toward the skull base, and usually changes treatment to wider excision with contrast MRI and adjuvant radiotherapy.
Is Mohs surgery appropriate for facial skin cancer?
Mohs micrographic surgery removes the tumour layer by layer with immediate microscopic margin control, sparing the maximum amount of normal tissue. It is particularly useful for basal cell and squamous cell cancers on the eyelids, nose, lips and ears, and for recurrent or poorly defined lesions where standard margins would cause avoidable deformity.
Can I continue immunotherapy for melanoma or advanced skin cancer while in China?
Often yes, but it must be arranged in advance. PD-1 inhibitors, CTLA-4 inhibitors and BRAF/MEK targeted agents are used in Chinese tertiary centres, yet the specific brand, dose, cycle interval, stock and price may differ from your home regimen. Continuing an established regimen without a verified plan risks an unplanned treatment gap.
What does head and neck skin cancer treatment cost in China?
Illustrative planning ranges are ¥20,000–¥80,000 (about US$2,800–11,000) for wide excision with local flap reconstruction and ¥80,000–¥180,000 for neck or parotid dissection with adjuvant radiotherapy. Immunotherapy and targeted agents are charged per cycle and may exceed the surgical cost. These are budgeting figures, not a quotation.
Sources for this topic
- Global Cancer Facts & Figures, 5th Edition (GLOBOCAN 2022 tables)
- Ultraviolet radiation and skin cancer (fact sheet)
- Global Cancer Observatory (GLOBOCAN 2022)
- NCCN Guidelines for Patients: Head and Neck Cancers
- Head and Neck Cancers (patient information)
- IARC Monographs on the Identification of Carcinogenic Hazards to Humans (tobacco, areca nut, UV radiation, EBV, HPV)
Ask about skin cancer of the head and neck treatment in China
Send your pathology report, biomarker results and imaging for a written preliminary opinion before making travel plans.
What to send Contact the clinicMedical disclaimer: This knowledge base is general information for people researching head and neck tumours, not a diagnosis or treatment plan. It does not replace an examination by a qualified physician. Survival figures are population averages, not predictions for an individual. Treatment and cost estimates for China are illustrative only and must be confirmed in writing after your records have been reviewed. If you have a symptom lasting more than two to three weeks, see a doctor promptly.